An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 21 Apr 2016 No of arms changed from 4 to 3 (removal of Daclatasvir + Asunaprevir arm).
- 27 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 18 Apr 2014 Planned End Date changed from 1 Feb 2017 to 1 Dec 2014 as reported by ClinicalTrials.gov record.